Novanta Inc.
NOVTTechnologyNASDAQScientific & Technical Instruments · Last scanned Sep 8, 2026
Scan Results
Daily timeframeHeadquartered within the technology sector, Novanta Inc. focuses on Scientific & Technical Instruments services and products. Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United. With a market capitalization of $5.61B, it sits in mid-cap territory. The company operates Automation Enabling Technologies and Medical Solutions segments.
Market Cap
$5.61B
Beta
1.68
P/E (TTM)
94.50
P/E (Fwd)
33.98
EPS (TTM)
$1.57
EPS (Fwd)
$4.37
ROE
5.1%
ROA
4.1%
Cash
$718.6M
Total Debt
$285.6M
Free CF
$118.4M
52W Change
28.8%
Annual Financials
Cash vs Debt
Where NOVT stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, NOVT finished 1.28% above its 150-day moving average ($142.69) and 5.37% above its 200-day moving average ($137.16). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NOVT overbought or oversold?
At the September 3, 2026 close, NOVT's RSI(14) was 25.9, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $718.6M in cash comfortably exceeding the $285.6M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company generates $118.4M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 5.1% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 4.1% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $706.8M (2021) to $980.6M (2025), reflecting a 39% increase over the period.
Novanta Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. At over 50x earnings, NOVT carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing NOVT.